Aug 4, 2017   SOURCE: PR NewsWire

First Radixact(TM) System Research Results Presented at the American Association of Physicists in Medicine Annual Meeting

SUNNYVALE, Calif., Aug. 4, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the first studies validating the benefits of the leading-edge Radixact(TM) System were presented at the 59th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Denver, Colorado, July 30 through August 3, 2017. This smart radiation therapy system represents the next generation in TomoTherapy® treatment delivery, significantly increasing treatment speed and ease of use. The Radixact System enables clinicians to treat a wide range of cancer cases, from initial plan delivery to adaptive therapy to complex retreatments, with precision and increased efficiency.

Research highlights include:

Faster planning and reduced treatment time

    --  A study evaluated the performance of the Radixact System based on a
        comparison of treatment plans developed for this system and the
        TomoHDA(TM) System. Treatment plans were created using the VoLO(TM)
        Planning Solution for the TomoHDA technology, then recreated using the
        Accuray Precision(TM) Treatment Planning System (TPS) for the Radixact
        System. Developing optimal plans using the Accuray Precision TPS was
        much faster, and the treatment beam-on time was reduced by up to 50%
        while maintaining the excellent plan quality. Researchers at the Miami
        Cancer Institute in Miami, Florida and Accuray Incorporated conducted
        the research.

Proven image quality and stability

    --  The first clinical assessment of Radixact low-dose fan beam MVCT image
        guidance found there was no statistically significant difference in the
        noise, uniformity, and Hounsfield units (HU) stability over the
        three-month evaluation period, demonstrating the strength of the
        System's MVCT image quality and its potential value for dose
        calculation. Clinicians at the Miami Cancer Institute team conducted the
        research.

Easy installation

    --  Radixact and TomoTherapy System dosimetric beam characteristics were
        compared over a six-month period. Radixact data were within the
        specifications established for the TomoTherapy System and showed a good
        agreement with the beam model. These results indicate that the beam
        commissioning process will be straightforward for the Radixact System.
        Researchers at Miami Cancer Institute and Accuray conducted the study.

The future of radiation therapy 

    --  Two studies demonstrated the feasibility of real-time motion management
        leveraging the TomoTherapy System's one-of-a-kind helical delivery
        capabilities.
        --  Accuray researchers investigated the potential for adapting the
            CyberKnife® System's unique Synchrony® Respiratory Tracking System
            to an experimental TomoTherapy System. The study showed
            Synchrony-like real-time respiratory motion management is
            technically feasible using TomoTherapy technology, enabling a high
            level of accuracy when delivering dose to tumors that move with
            respiration.
        --  The dosimetric impact of using real-time primary jaw/multileaf
            collimator (MLC) compensation approaches to mitigate motion during
            TomoHelical(TM) delivery was analyzed by a team of researchers from
            the University of Wisconsin, Madison and Accuray. Dose was
            calculated for treatment plans assuming 1) no motion, 2) respiratory
            motion, and 3) respiratory motion compensated by adjusting the jaw
            and MLC position during delivery. The team found that a jaw and MLC
            compensation approach mitigated the large difference between planned
            and delivered dose caused by motion, thus enabling reductions in
            margin.

"The data presented at this year's AAPM speak to the precision, accuracy and effectiveness of Accuray's entire portfolio of radiation therapy systems," said Calvin Maurer, Ph.D., Vice President and Chief Technology Officer at Accuray. "The Radixact(TM) System findings reinforce what customers are experiencing in their day-to-day practice and demonstrate its value to the radiation oncology team and their patients. In partnership with our customers we are continuing to develop clinically relevant technological advances such as the Radixact System, PreciseART(TM) Adaptive Solution and PreciseRTX(TM) Retreatment Option, which make it easier for clinicians to provide patients with the best possible treatment for them at each stage of their cancer treatment journey."

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, future developments of our technologies and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016 and April 29, 2016, and the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com

Danielle Sullivan
MSLGROUP
+1 (781) 684-6680
Danielle.sullivan@mslgroup.com

View original content with multimedia:http://www.prnewswire.com/news-releases/first-radixact-system-research-results-presented-at-the-american-association-of-physicists-in-medicine-annual-meeting-300499665.html

SOURCE Accuray Incorporated